A Phase I Study of 131-1 mIBG Followed by Nivolumab and Dinutuximab Beta in Children With Relapsed/Refractory Neuroblastoma
Latest Information Update: 12 Dec 2024
Price :
$35 *
At a glance
- Drugs Dinutuximab beta (Primary) ; Iobenguane (Primary) ; Nivolumab (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- Acronyms Inbraced; MiNivAN
- 10 Dec 2024 Planned primary completion date changed from 30 Sep 2024 to 30 May 2025.
- 10 Dec 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Apr 2024 Planned number of patients changed from 36 to 44.